Group 1: Telomir Pharmaceuticals Inc. (TELO) - Shares surged 43% in after-hours trading, climbing from $1.42 to $2.03 on light volume of 213,569 shares, below the average daily volume of 4.67 million [2] - The spike reflects renewed interest in recent in vitro data showing Telomir-1's ability to target additional histone demethylase families, indicating a unique epigenetic profile [3] Group 2: Processa Pharmaceuticals Inc. (PCSA) - Shares rose 32.6% in after-hours trading to $0.37, following a 30.9% gain during the regular session, with a closing price of $0.2790 on volume exceeding 31.9 million shares [4] - The price movement occurred without any official news or updates from the company, suggesting speculative momentum or technical positioning [5] Group 3: Reviva Pharmaceuticals Holdings Inc. (RVPH) - Shares increased 33.7% in after-hours trading to $0.8950 after a regular session gain of 22.8%, closing at $0.6693 with significant trading volume of 34.2 million shares [6] - The rally happened despite no recent official news, with the last update being four days prior regarding a healthcare conference [7] Group 4: NeuroOne Medical Technologies Corp. (NMTC) - Shares rose 9.5% in after-hours trading to $1.09, extending a 7.1% gain during the regular session, with a closing price of $0.9956 and trading volume of 1.21 million shares [8] - The increase followed the announcement of preliminary unaudited product revenue of $9.1 million for fiscal year 2025, up 163% from the prior year, and an upcoming virtual webinar [9] Group 5: BioRestorative Therapies Inc. (BRTX) - Shares edged 4.6% higher in after-hours trading to $1.60, following a modest 2% gain during the regular session, with a closing price of $1.53 and trading volume of 415,798 shares [10] - The increase followed the announcement of a $1.085 million registered direct offering priced at $1.60 per share, with proceeds aimed at advancing clinical trials and other corporate purposes [11]

Core Insights - Actelis Networks Inc (NASDAQ:ASNS) shares increased significantly in pre-market trading following the announcement of a new contract valued at approximately $0.3 million, which represents about 5.45% of the company's current market capitalization [1] Company Performance - Actelis Networks shares surged by 40.8%, reaching $0.52 in pre-market trading [2] - Other companies also experienced notable pre-market trading movements, with XCel Brands Inc (NASDAQ:XELB) gaining 49.7% to $2.59 and Cheer Holding Inc (NASDAQ:CHR) rising 45.8% to $0.19 [5]

Group 1: Reviva Pharmaceuticals Holdings Inc. (RVPH) - RVPH experienced a significant after-hours rally, increasing 18.27% to $0.58 after a 35.1% surge during regular trading, with a trading volume of over 40.5 million shares, nearly nine times its daily average [2][3] - The company has a market cap of $47 million and is focused on its lead candidate brilaroxazine, which targets neuropsychiatric and respiratory conditions [3] Group 2: Penumbra Inc. (PEN) - PEN surged 7.97% in after-hours trading to $273.69, following a 1.55% gain during the regular session, with a market cap nearing $9.9 billion [4][5] - The company has increased its revenue guidance for FY25 to a range of $1.355 billion - $1.370 billion, indicating a growth of 13% to 15% over 2024 [6] Group 3: Palisade Bio Inc. (PALI) - PALI jumped 10% in after-hours trading to $1.87, extending a 29.8% surge during the regular session, driven by a $138 million public offering [7][8] - The company has a market cap of $15.8 million and is gaining attention due to recent clinical updates and licensing agreements [8] Group 4: IO Biotech Inc. (IOBT) - IOBT rose 5.08% in after-hours trading to $0.4571, following a 22.3% surge during the regular session, with heavy trading volume of 16.7 million shares [9] - The company announced plans to design a new registrational study for its cancer vaccine candidate Cylembio after receiving regulatory feedback from the FDA [10] Group 5: Rallybio Corp. (RLYB) - RLYB increased 11.2% in after-hours trading to $0.5688, reversing a modest dip during the regular session, with a market cap of $21.4 million [11][12] - The company recently completed dosing in its Phase 1 study for RLYB116 and received a $12.5 million milestone payment for progress on the REV102 program [12] Group 6: Vor Biopharma Inc. (VOR) - VOR rose 3.6% in after-hours trading to $38.00, recovering from a 6.6% decline during the regular session, with a market cap of $251 million [13][14] - The company is focusing on its trem-cel platform and CD33-directed therapies for acute myeloid leukemia, alongside new executive appointments [14]

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][3] - The company will participate in the 4th Annual Roth Healthcare Opportunities Conference on October 9, 2025, where its CEO will engage in a panel discussion and host one-on-one investor meetings [1][2] Company Overview - Reviva's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] - The company has secured composition of matter patents for both drug candidates in the United States, Europe, and several other countries [3]

Core Insights - Biotech stocks experienced strong after-hours gains, driven by Pfizer's announcement of U.S. drug price cuts and a $70 billion investment in domestic manufacturing [1] Group 1: Ovid Therapeutics Inc. (OVID) - Ovid Therapeutics saw a 7.69% increase in after-hours trading, reaching $1.40 after a regular session decline of 7.14% to $1.30 [2] - The stock's regular session selloff was marked by elevated trading volume of over 2.93 million shares, significantly above the average of 2.07 million shares [2] - Recent coverage from Lucid Capital initiated a Buy rating with a price target of $5.50, highlighting Ovid's pipeline assets in Phase 1 trials for drug-resistant epilepsies [3] Group 2: NeuroOne Medical Technologies Corp. (NMTC) - NeuroOne Medical Technologies rose 6.98% in after-hours trading to $0.9506 after a modest decline of 1.27% during the regular session [4] - The trading volume was relatively light at 134,720 shares, below the average of 315,000 shares [4] - The company announced a virtual roadshow webinar scheduled for October 7 to discuss operations and recent FDA clearance [5] Group 3: PepGen Inc. (PEPG) - PepGen experienced a 3.03% rise in after-hours trading, reaching $4.76 after closing at $4.62 [6] - The stock has surged over 120% in the past week due to positive clinical and financial updates [6] - A recent $100 million public offering was completed, expected to support the development of PGN-EDODM1 and PGN-EDO51 [9] Group 4: Reviva Pharmaceuticals Holdings Inc. (RVPH) - Reviva Pharmaceuticals rose 5.81% in after-hours trading to $0.3900 after a 19.56% surge during the regular session [10] - The trading volume was significantly elevated at over 26 million shares, well above the average of 3.9 million shares [10] - The company recently announced a $9 million public offering priced at $0.30 per share [11] Group 5: Anika Therapeutics Inc. (ANIK) - Anika Therapeutics saw a 5.53% increase in after-hours trading, reaching $9.92 after closing at $9.40 [11] - The stock's regular session strength followed a quiet news cycle, with no new filings or press releases [12] - Anika is in focus ahead of its scheduled earnings report on October 30, 2025 [12]

Summary of Reviva Pharmaceuticals Holdings Conference Call Company Overview - Reviva Pharmaceuticals Holdings (NasdaqCM: RVPH) is a late-stage biopharmaceutical company focused on developing novel treatments for schizophrenia and other neuropsychiatric disorders [4][12] - The lead product, breloroxazine, is currently in phase three development for schizophrenia, with potential applications for bipolar disorder, major depressive disorder, and ADHD [12] Clinical Progress and Data - Reviva has treated over 900 patients across multiple trials, demonstrating good anti-inflammatory effects and robust efficacy in treating negative symptoms of schizophrenia [12][14] - The company has generated significant data supporting the efficacy of breloroxazine, particularly in reducing relapse rates and negative symptoms, which are major unmet needs in schizophrenia treatment [16][33] - Historical data indicates that 25% to 80% of patients on current treatments experience relapse, while Reviva's study showed minimal relapse rates [16][33][46] Mechanism of Action - Breloroxazine targets dysfunctional serotonin and dopamine pathways while also addressing inflammatory markers, which differentiates it from existing treatments [13][14] - The drug has shown a favorable side effect profile, with less than 1% incidence of motor side effects and comparable endocrine and metabolic side effects to placebo [17][42] Regulatory Outlook - Reviva plans to have a Type C meeting with the FDA in Q4 2025 to discuss the potential for an early NDA filing based on existing data [48][52] - The company believes it meets the statutory requirements for filing an NDA, having completed two randomized trials and a long-term safety study [49][50] Competitive Landscape - Reviva is aware of other companies developing schizophrenia treatments, such as LB Pharma, Neuron, and Neurocrine, but believes its approach is superior due to its unique mechanism and efficacy in addressing negative symptoms [9][65][66] - The company emphasizes the importance of addressing both primary and secondary negative symptoms for long-term treatment success [68][69] Key Metrics and Projections - The company has a buy rating with a 12-month price target of $3 per share [7] - Reviva's data shows a 10-point separation from placebo in efficacy, which is significantly better than historical data for other antipsychotics [29][30] Conclusion - Reviva Pharmaceuticals is positioned to potentially revolutionize the treatment of schizophrenia with breloroxazine, addressing significant unmet needs in the market while maintaining a strong safety profile and preparing for regulatory discussions with the FDA [19][52]

Core Insights - After-hours trading in the biotech and therapeutics sector saw significant price movements, particularly among small- and mid-cap companies, driven by clinical updates and strategic announcements [1] Company Summaries - **Cyclerion Therapeutics, Inc. (CYCN)**: Shares surged 48.01% to $4.47 after announcing a strategic relaunch focused on neuropsychiatric therapies, including a licensing agreement with MIT for its treatment-resistant depression program. The stock had closed at $3.02, down 0.66% during regular trading. A Phase 2 trial for the TRD program is expected to start in 2026, with initial data anticipated in 2027 [2][3] - **Clearside Biomedical Inc. (CLSD)**: The stock rose 6.82% to $4.23 after a regular session close of $3.96, despite a 9.79% decline during the day. The increase followed presentations at the EURETINA Congress regarding its Phase 2b ODYSSEY trial for wet age-related macular degeneration. The next key catalyst is the initiation of the Phase 3 trial, incorporating FDA feedback [3][4] - **Reviva Pharmaceuticals Holdings Inc. (RVPH)**: Shares increased by 11.50% to $0.32 after closing at $0.287, following a 6.61% decline during regular trading. The price action comes ahead of the company's participation in the Lytham Partners Fall 2025 Investor Conference [4][5] - **Acumen Pharmaceuticals, Inc. (ABOS)**: The stock advanced 5.69% to $1.30 after a regular session close of $1.23, despite a 3.91% decline during the day. The company reported that topline data from its Phase 2 ALTITUDE-AD trial is on track for late 2026 and plans to decide on advancing a preclinical candidate in early 2026 [5][6] - **PepGen Inc. (PEPG)**: Shares rose 5.13% to $2.05 after closing at $1.95, following an 8.02% decline during the day. The company completed patient dosing in its Phase 1 FREEDOM-DM1 trial and is on track to report topline data in early Q4 2025 [6][7] - **Corcept Therapeutics Inc. (CORT)**: The stock gained 4.54% to $87.10 after a regular session close of $83.32. The company announced it will present late-breaking data from its Phase 3 ROSELLA trial at the 2025 ESMO Annual Meeting. Two upcoming PDUFA dates were confirmed for relacorilant in hypercortisolism and platinum-resistant ovarian cancer [7][8][9]

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][3] - The company will present and host one-on-one investor meetings at the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 [1][2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] - The company has been granted composition of matter patents for both drug candidates in the United States, Europe, and several other countries [3]

Core Insights - The health care sector has several oversold stocks that present buying opportunities for undervalued companies [1] - The Relative Strength Index (RSI) is a key indicator for identifying oversold conditions, typically below 30 [1] Company Summaries - **Boston Scientific Corp (BSX)**: Upgraded from Perform to Outperform by Oppenheimer analyst Steven Lichtman, with a price target raised from $118 to $125. The stock has a 52-week low of $80.64 and an RSI value of 27.3. Recent price action shows a 0.3% decline, closing at $98.23 [7] - **aTyr Pharma Inc (ATYR)**: Announced that its Phase 3 EFZO-FIT study did not meet its primary endpoint, leading to an 80% stock decline over five days. The stock has a 52-week low of $0.97 and an RSI value of 22.6. Recent price action shows a 2.4% gain, closing at $1.05 [7] - **Reviva Pharmaceuticals Holdings Inc (RVPH)**: Announced a $9 million public offering, resulting in a 21% decline over the past month. The stock has a 52-week low of $0.30 and an RSI value of 24.5. Recent price action shows a 3.7% gain, closing at $0.42 [7]

Core Insights - The health care sector has identified oversold stocks, presenting potential buying opportunities for undervalued companies [1] - The Relative Strength Index (RSI) is a key indicator for assessing stock performance, with an RSI below 30 indicating oversold conditions [1] Company Summaries - **Boston Scientific Corp (BSX)**: Upgraded from Perform to Outperform by Oppenheimer analyst Steven Lichtman, with a price target raised from $118 to $125. The stock has fallen approximately 5% in the past five days, with a 52-week low of $80.64. Current RSI is 27.3, and shares closed at $98.23 [7] - **aTyr Pharma Inc (ATYR)**: Announced that its Phase 3 EFZO-FIT study did not meet its primary endpoint, leading to a stock decline of around 80% over the past five days, with a 52-week low of $0.97. Current RSI is 22.6, and shares closed at $1.05 [7] - **Reviva Pharmaceuticals Holdings Inc (RVPH)**: Recently priced a $9 million public offering, resulting in a stock decline of approximately 21% over the past month, with a 52-week low of $0.30. Current RSI is 24.5, and shares closed at $0.42 [7]